Publications by authors named "Miah Nicholls"
Article Synopsis
- BTK (Bruton's tyrosine kinase) is vital for B cell development and works downstream of the B cell receptor (BCR), alongside other kinases to relay signals that promote B cell survival and proliferation.
- BTK is linked to various B-cell lymphomas, leading to the development of targeted treatments like ibrutinib and pirtobrutinib, but certain mutations can cause resistance to these therapies.
- Research shows that BTK also has a non-catalytic scaffolding role that supports protein assembly and cell survival, highlighting new therapeutic opportunities that could improve B cell lymphoma treatments.
Article Synopsis
- SF3B1 mutations are common in cancer but lack directed treatments. Recent trials of XPO1 inhibitors in high-risk myelodysplastic neoplasms (MDS) found that patients with these mutations respond better to treatment.
- The study explores how these mutations affect RNA behavior when XPO1 is inhibited, leading to altered splicing and activation of apoptotic pathways in the mutant cells.
- Researchers identified that combining eltanexor (an XPO1 inhibitor) with venetoclax (a BCL2 inhibitor) effectively targets SF3B1 mutant cells while minimizing toxicity, paving the way for new treatment strategies for high-risk MDS.
STK17A is a novel uncharacterized member of the death-associated protein family of serine and threonine kinases. Overexpression of STK17A is observed in many cancers. We identified a lead compound that is based on a quinazoline core.
View Article and Find Full Text PDF